Fundz

Syntis Bio reported raising $6.32 Million in an initial SEC Form D filing, from an offering of $9 Million

PRIVATEJan 27, 2025$6.3M of $9M raised

Amount Raised

$6.32 Million

$6.32 Million sold, per SEC Form D (first sale Dec 30, 2024)

Round Type

Venture

MiltonBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as Syntis Bio that raised within 45 days of this round, from Fundz verified event records.

  • Junevity raised $10M (Seed) on February 13, 2025.
  • AudioCure Pharma raised an undisclosed amount (Funding Round) on February 13, 2025.
  • Latent Labs raised $50M (Series A) on February 13, 2025.
  • Newronika raised $14M (Series B) on February 13, 2025.
  • Kynda raised $3.1M (Seed) on February 13, 2025.
  • Exero Medical raised $13M (Seed) on February 13, 2025.

Who to call at Syntis Bio, and when

A new round usually means Syntis Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Syntis Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Syntis Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Syntis Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Syntis Bio

Location

Milton, Massachusetts, United States

About

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Syntis Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts hidden hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Syntis Bio's next move

See what Strategic adds

Syntis Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.